Regenetp (STU:NJT) Debt-to-Asset : 0.16 (As of Mar. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Regenetp Debt-to-Asset?

Regenetp's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was €0.43 Mil. Regenetp's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was €2.33 Mil. Regenetp's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2023 was €16.86 Mil. Regenetp's debt to asset for the quarter that ended in Mar. 2023 was 0.16.

Regenetp Debt-to-Asset Historical Data

The historical data trend for Regenetp's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenetp Debt-to-Asset Chart

Regenetp Annual Data

Trend

Oct13

Oct14

Oct15

Oct16

Oct17

Oct18

Dec19

Dec20

Dec21

Dec22

Debt-to-Asset

Get a 7-Day Free Trial

0.01

0.13

0.16

0.06

0.15

Regenetp Quarterly Data
	Apr18	Jul18	Oct18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Debt-to-Asset	Get a 7-Day Free Trial															0.05	0.04	0.03	0.15	0.16

Competitive Comparison of Regenetp's Debt-to-Asset

For the Biotechnology subindustry, Regenetp's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regenetp's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenetp's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Regenetp's Debt-to-Asset falls into.

Regenetp Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Regenetp's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.649	+	2.523)	/	21.568
	=	0.15

Regenetp's Debt-to-Asset for the quarter that ended in Mar. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.428	+	2.33)	/	16.858
	=	0.16

Regenetp (STU:NJT) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Regenetp Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Regenetp's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Regenetp (STU:NJT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenetp Inc (STU:NJT) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

RGTPQ:USA

Address

1960 South 4250 West, Salt Lake City, UT, USA, 84104

Website

https://www.polarityte.com

Regenetp Inc Formerly PolarityTE Inc is a clinical-stage biotechnology company developing regenerative tissue products and biomaterials. It's focused on transforming the lives of patients by discovering, designing, and developing regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences. Its product includes SkinTE used for repair, reconstruction, replacement, or regeneration of the skin in patients who have or require treatment of acute and chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. It operates in two segments: the regenerative medicine business segment and the contract research segment.

Regenetp (STU:NJT) Headlines

No Headlines